Patents by Inventor Marcus Karl Koppitz

Marcus Karl Koppitz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Tetrahydrocarbazol derivatives as ligands for G-protein-coupled receptors (GPCR)
    Patent number: 7122570
    Abstract: This invention provides new tetrahydrocarbazole derivatives that act as ligands for G-protein-coupled receptors (GPCR), especially as antagonists of the gonadotropin-releasing hormone (GnRH). A pharmaceutical composition that contains these new tetrahydrocarbazole derivatives as well as a process for the production of the new tetrahydrocarbazole derivatives are also provided. Moreover, this invention relates to the administration of tetrahydrocarbazole derivatives for treating pathologic conditions that are mediated by GPCR, especially for inhibiting GnRH, in mammals, especially humans, who require such an administration, as well as the use of tetrahydrocarbazole derivatives for the production of a pharmaceutical agent for treating GPCR-mediated pathologic conditions, especially for inhibiting GnRH.
    Type: Grant
    Filed: December 16, 2002
    Date of Patent: October 17, 2006
    Assignee: Zentaris AG
    Inventors: Marcus Karl Koppitz, Hans Peter Muhn, Kenneth Jay Shaw, Holger Hess-Stump, Klaus Paulini
  • Tetrahydrocarbazol derivatives as ligands for G-protein-coupled receptors (GPCR)
    Publication number: 20030232873
    Abstract: This invention provides new tetrahydrocarbazole derivatives that act as ligands for G-protein-coupled receptors (GPCR), especially as antagonists of the gonadotropin-releasing hormone (GnRH). A pharmaceutical composition that contains these new tetrahydrocarbazole derivatives as well as a process for the production of the new tetrahydrocarbazole derivatives are also provided. Moreover, this invention relates to the administration of tetrahydrocarbazole derivatives for treating pathologic conditions that are mediated by GPCR, especially for inhibiting GnRH, in mammals, especially humans, who require such an administration, as well as the use of tetrahydrocarbazole derivatives for the production of a pharmaceutical agent for treating GPCR-mediated pathologic conditions, especially for inhibiting GnRH.
    Type: Application
    Filed: December 16, 2002
    Publication date: December 18, 2003
    Applicant: ZENTARIS AG
    Inventors: Marcus Karl Koppitz, Hans Peter Muhn, Kenneth Jay Shaw, Holger Hess-Stumpp, Klaus Wolfgang Paulini